“…The updated approach was guided by (1) the low risk of EOS in well-appearing late-preterm and term infants regardless of risk factors, 1,7,8,11,16,17 (2) the limited clinical utility of CBC counts and C-reactive proteins (CRPs) to guide antibiotic treatment decisions in well-appearing infants, 15,18,19 and (3) the potential utility of clinical examination to identify EOS in at-risk infants. 20,21 Our specific aim was to reduce unnecessary antibiotic exposure and laboratory testing in well-appearing, late-preterm and term, chorioamnionitis-exposed infants. The objective of the current quality-improvement (QI) report was to evaluate the impact of the new care approach after the first 15 months of implementation.…”